Amgen’s (NASDAQ:AMGN) tarlatamab, known as Imdyllytra, has received approval from the U.K.’s Medicines and Healthcare products Regulatory Agency. This approval targets small cell lung cancer that has metastasized throughout the lungs or to other parts of the body. In clinical trials, 90% of patients treated with tarlatamab showed a response to the therapy. This new treatment option could significantly impact the market for lung cancer treatments, given the high response rate observed in trials.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
